Latest news with #RCKT
Business Wire
6 hours ago
- Business
- Business Wire
Securities Fraud Investigation Into Rocket Pharmaceuticals, Inc. (RCKT) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm
LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Rocket Pharmaceuticals, Inc. ('Rocket' or the 'Company') (NASDAQ: RCKT) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ROCKET PHARMACEUTICALS, INC. (RCKT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On May 27, 2025, Rocket disclosed that the FDA had placed a clinical hold on the Phase 2 pivotal trial of its Danon disease treatment, RP-A501, after at least one patient died following a substantive amendment to the protocol that the Company had not disclosed until after the Serious Adverse Event ('SAE') occurred. On this news, Rocket's stock price fell $3.94, or 62.8%, to close at $2.33 per share on May 27, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us. Charles Linehan, Esq., Glancy Prongay & Murray LLP, 1925 Century Park East, Suite 2100, Los Angeles California 90067 Email: shareholders@ Telephone: 310-201-9150 (Toll-Free: 888-773-9224) Visit our website at Follow us for updates on LinkedIn, Twitter, or Facebook. Whistleblower Notice Persons with non-public information regarding Rocket should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@ About Glancy Prongay & Murray LLP Glancy Prongay & Murray LLP ('GPM') is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. GPM has been consistently ranked in the Top 50 Securities Class Action Settlements by ISS Securities Class Action Services. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM's nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM's lawyers have handled cases covering a wide spectrum of corporate misconduct and relating to nearly all industries and sectors. GPM's past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron's, Investor's Business Daily, Forbes, and Money. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
8 hours ago
- Business
- Business Wire
Rocket Pharmaceuticals, Inc. (RCKT) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Rocket Pharmaceuticals, Inc. ('Rocket' or the 'Company') (NASDAQ: RCKT) investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN ROCKET PHARMACEUTICALS, INC. (RCKT), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@ by telephone at (215) 638-4847 or visit our website at What Happened? On May 27, 2025, Rocket disclosed that the FDA had placed a clinical hold on the Phase 2 pivotal trial of its Danon disease treatment, RP-A501, after at least one patient died following a substantive amendment to the protocol that the Company had not disclosed until after the Serious Adverse Event ('SAE') occurred. On this news, Rocket's stock price fell $3.94, or 62.8%, to close at $2.33 per share on May 27, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Rocket securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, Telephone: (215) 638-4847 Email: howardsmith@ Visit our website at: This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Associated Press
2 days ago
- Business
- Associated Press
Securities Fraud Investigation Into Rocket Pharmaceuticals, Inc. (RCKT) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES--(BUSINESS WIRE)--Jun 18, 2025-- The Law Offices of Frank R. Cruz announces an investigation of Rocket Pharmaceuticals, Inc. ('Rocket' or the 'Company') (NASDAQ: RCKT ) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ROCKET PHARMACEUTICALS, INC. (RCKT), CLICKHERETO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On May 27, 2025, Rocket disclosed that the FDA had placed a clinical hold on the Phase 2 pivotal trial of its Danon disease treatment, RP-A501, after at least one patient died following a substantive amendment to the protocol that the Company had not disclosed until after the Serious Adverse Event ('SAE') occurred. On this news, Rocket's stock price fell $3.94, or 62.8%, to close at $2.33 per share on May 27, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Rocket securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: The Law Offices of Frank R. Cruz 2121 Avenue of the Stars, Suite 800 Century City, California 90067 Call us at: 310-914-5007 Email us at: [email protected] Visit our website at: Follow us for updates on Twitter at If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. View source version on CONTACT: The Law Offices of Frank R. Cruz, Los Angeles Frank R. Cruz 310-914-5007 [email protected] KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA INDUSTRY KEYWORD: CLASS ACTION LAWSUIT PROFESSIONAL SERVICES LEGAL SOURCE: The Law Offices of Frank R. Cruz Copyright Business Wire 2025. PUB: 06/18/2025 07:30 PM/DISC: 06/18/2025 07:31 PM
Business Wire
2 days ago
- Business
- Business Wire
Securities Fraud Investigation Into Rocket Pharmaceuticals, Inc. (RCKT) Announced – Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz announces an investigation of Rocket Pharmaceuticals, Inc. ('Rocket' or the 'Company') (NASDAQ: RCKT) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ROCKET PHARMACEUTICALS, INC. (RCKT), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO RECOVER YOUR LOSS. What Is The Investigation About? On May 27, 2025, Rocket disclosed that the FDA had placed a clinical hold on the Phase 2 pivotal trial of its Danon disease treatment, RP-A501, after at least one patient died following a substantive amendment to the protocol that the Company had not disclosed until after the Serious Adverse Event ('SAE') occurred. On this news, Rocket's stock price fell $3.94, or 62.8%, to close at $2.33 per share on May 27, 2025, thereby injuring investors. Contact Us To Participate or Learn More: If you purchased Rocket securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us: The Law Offices of Frank R. Cruz 2121 Avenue of the Stars, Suite 800 Century City, California 90067 Call us at: 310-914-5007 Email us at: info@ Visit our website at: Follow us for updates on Twitter at If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Upturn
2 days ago
- Business
- Business Upturn
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Rocket Pharmaceuticals, Inc. (RCKT) Shareholders
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) — The Gross Law Firm issues the following notice to shareholders of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT). Shareholders who purchased shares of RCKT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: Rocket Loss Submission Form CLASS PERIOD: February 27, 2025 to May 26, 2025 ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket knew Serious Adverse Events (SAEs), including death of participants enrolled in the study, were a risk. In particular, Rocket amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Rocket's securities at artificially inflated prices. On May 27, 2025, Rocket announced that the FDA placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event (SAE), ultimately, death, while enrolled in the study following a substantive amendment to the protocol that the Company failed to disclose to investors at the time management made the revision. In fact, Rocket stated that, while the patient was dosed in May, the decision to amend the protocol was made 'several months' earlier. Despite this, Rocket made no attempt to alert investors or the public to the change until after the SAE occurred. Following this news, the price of Rocket's common stock declined dramatically. From a closing market price of $6.27 per share on May 23, 2025, Rocket's stock price fell to $2.33 per share on May 27, 2025, a decline of about 37% in the span of just a single trading day. DEADLINE: August 11, 2025 Shareholders should not delay in registering for this class action. Register your information here: NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of RCKT during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 11, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018 Email: [email protected] Phone: (646) 453-8903
